Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis

Virology

Volumn 310, Issue 1, 2003, Pages 16-23

  Tözsér, József ^a   Shulenin, Sergey ^b   Kádas, János ^a   Boross, Péter ^a   Bagossi, Péter ^a   Copeland, Terry D ^b   Nair, Bala C ^c   Sarngadharan, Mangalasseril G ^c   Oroszlan, Stephen ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

Enzyme kinetics; HIV 1 capsid protein; HIV 1 proteinase; Integrase; Oligopeptide substrates

Indexed keywords

ALANINE; CAPSID PROTEIN; CYCLOPHILIN A; INTEGRASE; LEUCINE; PROTEINASE; VIRUS ENZYME;

ACIDITY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; METABOLISM; PH;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

CAPSID PROTEINS; CYCLOPHILIN A; HIV INTEGRASE; HIV PROTEASE; HIV-1; HYDROGEN-ION CONCENTRATION;

EID: 0037530288     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00074-6     Document Type: Article

References (50)

1. Baboonian C., Dalgleish A., Bountiff L., Gross J., Oroszlan S., Rickett G., Smith-Burchnell C., Troke P., Merson J. HIV-1 proteinase is required for synthesis of pro-viral DNA. Biochem. Biophys. Res. Commun. 179:1991;17-24.
2. Berthet-Colominas C., Monaco S., Novelli A., Sibai G., Mallet F., Cusack S. Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J. 18:1999;1124-1136.
3. Boross P., Bagossi P., Copeland T.D., Oroszlan S., Louis J.M., Tözsér J. Effect of substrate residues on the P2′ preference of retroviral proteinases. Eur. J. Biochem. 264:1999;921-929.
4. Braaten D., Franke E.K., Luban J. Cyclophilin A is required for early step in the life cycle of human immunodeficiency virus type 1 before initiation of reverse transcription. J. Virol. 70:1996;3551-3560.
5. Dietrich L., Ehrlich L.S., LaGrassa T.J., Ebbets-Reed D., Carter C. Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein. J. Virol. 75:2001;4721-4733.
6. Ehrlich L.S., Liu T., Scarlata S., Chu B., Carter C.A. HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro structure switching by pH-induced conformational changes. Biophys. J. 81:2001;586-594.
7. Eron J.J. HIV-1 protease inhibitors. Clin. Infect. Dis. 30:(Suppl. 2):2000;S160-S170.
8. Fackler O.T., Peterlin B.M. Endocytic entry of HIV-1. Curr. Biol. 10:2000;1005-1008.
9. Farnet C.M., Haseltine W.A. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J. Virol. 65:1991;1910-1915.
10. Franke E.K., Yuan H.E., Luban J. Specific incorporation of cyclophylin A into HIV-1 virions. Nature. 372:1994;359-362.
11. Goto T., Nakano T., Kohno T., Morimatsu S., Morita C., Hong W., Kiso Y., Nakai M., Sano K. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells. J. Med. Virol. 63:2001;203-209.
12. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-467.
13. Grewe C., Beck A., Gelderblom H.R. HIV early virus-cell interactions. J. Acquir. Immune Defic. Syndr. 3:1990;965-974.
14. Grobelny D., Wondrak E.M., Galardy R.E., Oroszlan S. Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem. Biophys. Res. Commun. 169:1990;1111-1116.
15. Ishima R., Ghirlando R., Tözsér J., Gronenborn A.M., Torchia D.A., Louis J.M. Folded monomer of HIV-1 protease. J. Biol. Chem. 276:2001;49110-49116.
16. Jacobsen H., Ahlborn-Laake J., Gugel R., Mous J. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease. J. Virol. 66:1992;5087-5092.
17. Jenkins T.M., Engelman A., Ghirlando R., Craigie R. A soluble active mutant of HIV-1 integrase involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 271:1996;7712-7718.
18. Kaplan A.H., Manchester M., Smith T., Yang Y.L., Swanstrom R. Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J. Virol. 70:1996;5840-5844.
19. Korber, B., Kuiken, C., Foley, B., Hahn, B., McCuthan, F., Mellors, J., Sodroski, J., (Eds.), 1998. Human Retroviruses and AIDS, Los Alamos, NM.
20. Louis J.M., McDonald R., Nashed N., Wondrak E.M., Jerina D., Oroszlan S., Mora P. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. Eur. J. Biochem. 199:1991;361-369.
21. Louis J.M., Weber I.T., Tözsér J., Clore G.M., Gronenborn A.M. HIV-1 protease maturation, enzyme specificity and drug resistance. Adv. Pharmacol. 49:2000;111-146.
22. Mely Y., De Rocquigny H., Morellet N., Roques B.P., Gerad D. Zinc binding to the HIV-1 nucleocapsid protein a thermodynamic investigation by fluorescence spectroscopy. Biochemistry. 35:1996;5175-5182.
23. Mildner A.M., Rothrock D.J., Leone J.W., Bannow C.A., Lull J.M., Reardon I.M., Sarcich J.L., Howe J., Tomich C.S., Smith C.W., Heinrickson R.L., Tomasselli A.G. The HIV-1 protease as enzyme and substrate mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry. 33:1994;9405-9413.
24. Miller M.D., Farnet C.M., Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes studies of organization and composition. J. Virol. 71:1997;5382-5390.
25. Misselwitz R., Hausdorf G., Welfle K., Hohne W.E., Welfle H. Conformation and stability of recombinant HIV-1 capsid protein p24 (rp24). Biochim. Biophys. Acta. 1250:1995;9-18.
26. Nagy K., Young M., Baboonian C., Merson J., Whittle P., Oroszlan S. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection evidence for a role of protease in the early phase. J. Virol. 68:1994;757-765.
27. Oroszlan S., Luftig R.B. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157:1990;153-185.
28. Panther L.A., Coombs R.W., Aung S.A., dela Rosa C., Gretch D., Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells relative effect of recombinant CD4, zidovudine and saquinavir in vitro. J. Med. Virol. 58:1999;165-173.
29. Pettit S.C., Moody M.D., Wehbie R.S., Kaplan A.H., Nantermet P.V., Klein C.A., Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:1994;8017-8027.
30. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 224:1984;497-500.
31. Roberts M.M., Copeland T.D., Oroszlan S. In situ processing of a retroviral nucleocapsid protein by the viral proteinase. Protein Eng. 4:1991;695-700.
32. Roberts M.M., Oroszlan S. The preparation and biochemical characterization of intact capsids of equine infectious anemia virus. Biochem. Biophys. Res. Commun. 160:1989;486-494.
33. Roberts M.M., Volker E., Copeland T.D., Nagashima K., Cassel M.B., Briggs C.J., Oroszlan S. Regulated proteolytic processing within mature retroviral capsids. Kumar A. Advances in Molecular Biology and Targeted Treatment for AIDS. 1991;273-280 Plenum Press, New York.
34. Sherman M.P., de Noroncha C.M., Heusch M.I., Greene S., Greene W.C. Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J. Virol. 75:2001;1522-1532.
35. Steinkasserer A., Harrison R., Billich A., Hammersmid F., Werner G., Wolff B., Peichl P., Palfi G., Schnitzel W., Mlynar E., Rosenwirth B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus 1 (HIV-1) interference with early and late events in HIV-1 replication. J. Virol. 69:1995;814-824.
36. Thali M., Bukovsky A., Kondo E., Rosenwirth B., Walsh C., Sodorski J., Göttlinger H.G. Functional association of cyclophilin A with HIV-1 virions. Nature. 372:1994;363-365.
37. Tomasselli A.G., Heinrickson R.L. Specificity of retroviral proteases an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:1994;279-301.
38. Tomasselli A.G., Sardich J.L., Barrett L.J., Reardon I.M., Howe W.J., Evans D.B., Sharma S.K., Heinrickson R.L. Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci. 2:1993;2167-2176.
39. Tong L., Pav S., Pargellis C., Do F., Lamerre D., Anderson P.C. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. Proc. Natl. Acad. Sci. USA. 90:1993;8387-8391.
40. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
41. Tözsér J., Bláha I., Copeland T.D., Wondrak E.M., Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:1991;77-80.
42. Tözsér J., Weber I.T., Gustchina A., Bláha I., Copeland T.D., Louis J.M., Oroszlan S. Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases. Biochemistry. 31:1992;4793-4800.
43. Tsai W.P., Nara P.L., Kung H.F., Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res. Hum. Retroviruses. 6:1990;481-489.
44. Uchida H., Maeda Y., Mitsuya H. HIV-1 protease does not play a critical role in the early phase of HIV-1 infection. Antiviral Res. 36:1997;107-113.
45. Veronese F.D., Copeland T.D., Oroszlan S., Gallo R.C., Sarngadharan M.G. Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J. Virol. 62:1988;795-801.
46. Weber I.T., Wu J., Adomat J., Harrison R.W., Kimmel A.R., Wondrak E.M., Louis J.M. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate - interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur. J. Biochem. 249:1997;523-539.
47. Welker R., Hohenberg H., Tessmer U., Huckhagel C., Krausslich H.G. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74:2000;1168-1177.
48. Welker R., Kottler H., Kalbitzer H.R., Krausslich H.G. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology. 219:1996;228-236.
49. Wlodawer A., Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:1993;543-585.
50. Wondrak E.M., Sakaguchi K., Rice W.G., Kun E., Kimmel A.R., Louis J.M. Removal of zinc is required for processing of the mature nucleocapsid protein of human immunodeficiency virus, type 1, by the viral protease. J. Biol. Chem. 269:1994;21948-21950.